FDA Approves Genentech ' s Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

South San Francisco, CA -- April 18, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news